Chronic Suppurative Gingivitis: A Rare Manifestation of Lichen Planus Following SARS-COV 2 Infection
Main Article Content
Abstract
Post-COVID-19 chronic suppurative gingivitis is an emerging clinical entity that has attracted increasing interest in the medical and dental community because of its association with SARS-CoV-2 virus infection and its prolonged and potentially debilitating manifestation in the periodontal system. This article provides a comprehensive review of this entity, addressing its epidemiology, pathogenesis, clinical manifestations, diagnosis and current therapeutic approaches.
The epidemiology of post-COVID-19 chronic suppurative gingivitis is characterized by its occurrence following SARS-CoV-2 infection, with a variable incidence in convalescent patients. A higher prevalence has been observed in individuals with underlying systemic diseases, such as diabetes mellitus and arterial hypertension, suggesting an individual susceptibility component.
From a pathogenic perspective, it has been postulated that SARS-CoV-2 infection could trigger an overactive immune response and chronic inflammation at the gingival level, contributing to persistent suppurative gingivitis. The involvement of viral factors and host response in the pathogenesis of this entity are under ongoing investigation.
The clinical presentation of post-COVID-19 chronic suppurative gingivitis includes characteristic signs such as gingivorrhage, gingival edema, superficial ulcerations, and the production of purulent exudate in the gums. These findings, in combination with a history of SARS-CoV-2 infection, are critical for diagnosis.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Álvarez Jiménez, A., Sarduy Bermúdez, L., & Rodríguez Felipe, M. (2022). Chronic desquamative gingivitis: a gingival manifestation of oral lichen planus. Medicentro ElectróNica, 26(1), 186-194.
II. Cooperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine and Growth Factor Reviews, 53, 25-32.
III. Zou, H., & Daveluy, S. (2023). Lichen planus after COVID-19 infection and vaccination. Archives of dermatological research, 315(2), 139-146.
IV. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: A comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. Sci World J. 2014;2014:742826. doi: 10.1111/dth.13476.
V. tancioiu F., Papadakis G.Z., Kteniadakis S., Izotov B.N., Coleman M.D., Spandidos D.A., et al. A dissection of SARS-CoV2 with clinical implications (Review) Int J Mol Med. 2020;46:489-508. doi: 10.1111/dth.13476.
VI. Galván Casas C., Català A., Carretero Hernández G., Rodríguez-Jiménez P., Fernández-Nieto D., Rodríguez-Villa Lario A., et al. Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71-77. doi: 10.1111/dth.13476.
VII. Türsen Ü., Türsen B., Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther. 2020;33:e13476. doi: 10.1111/dth.13476.